



**MEDICAMENTS LTD.**

Reg. Office: 604, 6th floor, Meghdoot, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai - 400049

Email ID: rubraltd@gmail.com | Website: www.rubramed.com

CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

---

February 11, 2022

To,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001

**Scrip Code** : **531099**  
**Sub** : **Outcome of Board Meeting**

Dear Sir / Madam,

This is to inform you that the Board of Directors of the Company at its meeting held on Friday, February 11, 2022, inter alia, has considered and approved the following:

- A. Unaudited Standalone Financial Results along with Limited review report for the quarter ended December 31, 2021
- B. Change in name of the Company to new name subject to approval of the members of the Company and other statutory authorities and calling of Members meeting.

You are requested to kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Rubra Medicaments Limited**



**Abha Kapoor**  
**Director (Finance) and CFO**  
**DIN – 02799429**

## Rubra Medicaments Ltd.

### Statement of Standalone Unaudited Financial Results for the quarter ended December 31, 2021

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Year to date Figures for current period ended	Year to date Figures for previous period ended	Figures for the previous year ended
		31-Dec-2021	30-Sep-2021	31-Dec-2020	31-Dec-2021	31-Dec-2020	31-Mar-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	43.50	26.00	10.00	139.11	18.75	48.50
II	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
III	<b>Total Income (I + II)</b>	<b>43.50</b>	<b>26.00</b>	<b>10.00</b>	<b>139.11</b>	<b>18.75</b>	<b>48.50</b>
IV	<b>Expenses:</b>						
	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	1.92	0.00	0.00	51.99	0.00	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	Employee benefits Expense	2.07	7.52	1.89	10.36	3.09	19.54
	Finance Costs	0.00	0.01	0.00	0.02	0.01	0.04
	Depreciation & amortisation expense	0.04	0.04	0.04	0.12	0.12	0.16
	Other Expenses	43.55	16.42	7.96	77.78	15.41	19.68
	<b>Total Expenses (IV)</b>	<b>47.58</b>	<b>23.99</b>	<b>9.89</b>	<b>140.27</b>	<b>18.63</b>	<b>47.68</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>-4.08</b>	<b>2.01</b>	<b>0.11</b>	<b>-1.16</b>	<b>0.12</b>	<b>0.82</b>
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V-VI)</b>	<b>-4.08</b>	<b>2.01</b>	<b>0.11</b>	<b>-1.16</b>	<b>0.12</b>	<b>0.82</b>
VIII	Tax Expense:						
	(1) Current tax	0.00	0.60	0.00	0.80	0.00	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-4.08</b>	<b>1.41</b>	<b>0.11</b>	<b>-1.96</b>	<b>0.12</b>	<b>0.57</b>
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit/(loss) from Discontinuing operations (after tax)(X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX+XII)</b>	<b>-4.08</b>	<b>1.41</b>	<b>0.11</b>	<b>-1.96</b>	<b>0.12</b>	<b>0.57</b>
XIV	Other comprehensive income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-4.08	1.41	0.11	-1.96	0.12	0.57
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.00	0.03	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.03	0.00	0.00	0.00	0.01
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic						
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	Earnings per equity share (for discontinued & continuing operation):						
	(1) Basic	0.00	0.03	0.00	0.00	0.00	0.01
	(2) Diluted	0.00	0.03	0.00	0.00	0.00	0.01
	<b>NOTES:</b>						
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.						
3	The result is provisional and unaudited and subject to change, regrouping and restatement.						

For Rubra Medicaments Limited

Place: Mumbai  
Date:- February 11, 2022

  
 Abha Kapoor  
 Director (Finance) & CFO  
 DIN: 02799429



# DD & COMPANY

## CHARTERED ACCOUNTANTS

**The Limited Review Report for listed entities other than banks and insurance companies - unaudited standalone quarterly and year to date results**

To,

**The Board of Directors  
Rubra Medicaments Ltd.  
Mumbai**

We have reviewed the accompanying statement of unaudited financial results of Rubra Medicaments Ltd. for the period ended December 31, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai  
Date: February 11, 2022

For M/s DD & Company  
Chartered Accountants  
Firm Registration No. FRN/29273W



Proprietor  
Membership No: 045393  
UDIN:22045393ABINFQ7864

705, MORYA BLUEMOON, NEAR MONGINIS CAKE FACTORY, OPP CITI MALL, LINK ROAD,  
ANDHERI WEST, MUMBAI - 400053 CELL NO: 9820700430 / 9821299981  
TEL NO: 62215449; 66712284 Email: [andherica@gmail.com](mailto:andherica@gmail.com)  
Web: [www.dhagarwal.com](http://www.dhagarwal.com) [www.ddmumbai.com](http://www.ddmumbai.com)